MYGN Message Board - Msg: 4032909

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MYGN

MYGN 6.295

-3.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Lee Allgood who wrote (15)	4/11/1998 2:50:00 PM
From: A.J. Mullen	Read Replies (1) of 29

I've been typing to myself for sometime on "Myriad Genetics." Glad to find you people. The Tomixifen study seems important to me. I hope someone will go back to the participants and test them using Myriad's tests, and see how the statistics would look if the drug had only been given to those participants whose risk had been confirmed by Myriad. The newspaper report I read gave fairly detailed results that suggested the case for Tamoxifen as a prophylactic was anything but clear-cut for the high-risk women of the study. (So blurred, in fact, that I am surprised the study was halted.) If those who had tested negative in Brac tests had been excluded from the trial, then I suspect the results would have been a clearer indication that women with positive Brac tests should take the Tamoxifen. aj

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next